SK3 Group, Inc. (SKTO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
SK3 Group, Inc. (SKTO) trades at $0.00001. SK3 Group, Inc. operates within the medical marijuana sector, providing management advisory, licensing, and marketing services. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SKTO: SKTO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SKTO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SKTO: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →SK3 Group, Inc. (SKTO) Healthcare & Pipeline Overview
SK3 Group, Inc. provides management, licensing, and marketing services to medical marijuana collectives in California, focusing on proprietary technologies and licensed products such as edibles and delivery systems. The company operates in a highly regulated and evolving market within the specialty and generic drug manufacturing industry.
What Is the Investment Thesis for SKTO?
SK3 Group, Inc. operates in the niche market of providing services to medical marijuana collectives in California. With a market capitalization of $0.00B, the company's financial performance, indicated by a profit margin of 0.3% and a gross margin of 71.9%, suggests potential for improvement in operational efficiency and revenue generation. The negative free cash flow of $-0.00B indicates a need for careful cash management. The company's beta of -24.08 suggests an inverse correlation with the market. Growth catalysts include the potential expansion of its licensing agreements and the increasing acceptance of medical marijuana. Key risks include regulatory changes and competition from larger players in the cannabis industry.
Based on FMP financials and quantitative analysis
SKTO Key Highlights
Gross margin of 71.9% indicates strong pricing power in its licensing and marketing services.
- Profit margin of 0.3% suggests potential for improved operational efficiency.
- Negative free cash flow of $-0.00B requires careful monitoring of cash management.
- Beta of -24.08 indicates an inverse correlation with the market.
- The company operates as a subsidiary of Healthcare of Today, Inc.
Who Are SKTO's Competitors?
SKTO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SKTO's Key Strengths?
Proprietary Dharmanol technology.
- Established presence in the California medical marijuana market.
- Licensing agreements for various medical marijuana products.
- Focus on management advisory services for collectives.
What Are SKTO's Weaknesses?
Small market capitalization.
- Limited geographic reach (California only).
- Dependence on the regulatory environment of California.
- Negative free cash flow.
What Could Drive SKTO Stock Higher?
Potential changes in federal regulations regarding marijuana could open up new markets and opportunities.
- Increasing acceptance of medical marijuana for various conditions may drive demand for licensed products.
- Expansion of licensing agreements with medical marijuana collectives.
What Are the Key Risks for SKTO?
Changes in California state regulations regarding medical marijuana could negatively impact operations.
- Increased competition from larger cannabis companies with greater resources.
- Negative free cash flow requires careful monitoring and management.
- Product liability claims related to medical marijuana products.
What Are the Growth Opportunities for SKTO?
- Expansion of Product Licensing: SK3 Group, Inc. can expand its revenue streams by licensing additional cannabis-related products. The market for cannabis products is projected to reach $35 billion by 2027, offering substantial opportunities for growth through strategic partnerships and licensing agreements with innovative product developers. This expansion could include new formulations, delivery methods, or therapeutic applications, broadening the company's market reach and appeal.
- Geographic Expansion within California: While currently focused on California, SK3 Group, Inc. can pursue growth by expanding its services to more regions within the state. California's cannabis market is one of the largest in the United States, with sales projected to reach $7 billion by 2026. By targeting underserved areas and establishing relationships with new medical marijuana collectives, the company can increase its market share and revenue.
- Development of Proprietary Technologies: SK3 Group, Inc. can invest in the development of new proprietary technologies, building upon its existing Dharmanol technology. Focusing on extraction, stabilization, and delivery methods for cannabinoids, the company can create unique and valuable intellectual property. The market for cannabis extraction technologies is expected to grow, driven by the increasing demand for high-quality cannabis extracts and concentrates.
- Strategic Partnerships and Acquisitions: SK3 Group, Inc. can pursue strategic partnerships or acquisitions to expand its service offerings and market reach. Collaborating with complementary businesses, such as testing labs, distribution companies, or cultivation facilities, can create synergies and enhance the company's value proposition. Targeted acquisitions can provide access to new technologies, products, or customer segments, accelerating growth and diversification.
- Focus on Research and Development: Investing in research and development to explore new applications for cannabinoids can drive long-term growth. By collaborating with research institutions and conducting clinical trials, SK3 Group, Inc. can identify novel therapeutic uses for its products and technologies. This can lead to the development of innovative products that address unmet medical needs, creating a competitive advantage and driving revenue growth.
What Are SKTO's Competitive Advantages?
- Proprietary Dharmanol technology for cannabinoid extraction and preservation.
- Established relationships with medical marijuana collectives in California.
- Licensing agreements for unique medical marijuana products.
What Does SKTO Do?
Founded in 2000 and formerly known as CTT International Distributors, Inc., SK3 Group, Inc. shifted its focus to the medical marijuana sector in 2007. Headquartered in Los Angeles, California, the company operates as a subsidiary of Healthcare of Today, Inc. SK3 Group, Inc. specializes in providing management advisory, licensing, and marketing services to medical marijuana collectives within California. Its core business revolves around licensing various products, including the YAK line of medical marijuana edibles, Canna-Loz, a delivery system for phyto-cannabinoids, and Yeti, a pre-roll product designed for pain relief. A key element of their offerings is Dharmanol, a proprietary technology focused on the extraction, stabilization, and preservation of medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. The company's activities are concentrated within the California market, navigating the state's specific regulatory landscape for medical marijuana.
What Products and Services Does SKTO Offer?
- Provides management advisory services to medical marijuana collectives.
- Licenses medical marijuana-related products for marketing and sale.
- Offers the YAK line of medical marijuana edibles.
- Provides Canna-Loz, a delivery system for phyto-cannabinoids.
- Licenses Yeti, a pre-roll product for pain relief.
- Offers Dharmanol, a proprietary technology for cannabinoid extraction and preservation.
How Does SKTO Make Money?
- Generates revenue through licensing fees from medical marijuana products.
- Provides management advisory services to medical marijuana collectives for a fee.
- Markets and sells licensed products through established distribution channels.
What Industry Does SKTO Operate In?
SK3 Group, Inc. operates within the Drug Manufacturers - Specialty & Generic industry, specifically catering to the medical marijuana sector in California. This industry is characterized by evolving regulations, increasing competition, and growing market acceptance of cannabis-based products for medicinal use. The company's focus on licensing and marketing services positions it within a segment that supports the broader cultivation, processing, and distribution activities within the cannabis value chain. The industry faces ongoing challenges related to federal regulations, interstate commerce restrictions, and the need for standardized quality control measures.
Who Are SKTO's Key Customers?
- Medical marijuana collectives in California.
- Patients seeking medical marijuana products for various conditions.
- Distributors of medical marijuana products.
Key Financial Metrics
Return on equity for SK3 Group, Inc. stands at 133.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 59.6%, showing how much profit it generates from its asset base. SKTO trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 10.04 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
SK3 Group, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Los Angeles, US. The company is led by CEO Artemus Mayor. SKTO has traded publicly since 2008.
Financial Health
SK3 Group, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
SKTO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in SK3 Group's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative projects and strategic direction.
- There is growing interest in the sector SK3 operates in, with potential for expansion and increased market share, driving optimism.
- Recent partnerships and collaborations have generated buzz, enhancing the company's visibility and perceived value in the market.
Bear Case
- Despite positive sentiment, some community members express concerns over the company's financial stability and operational challenges.
- Recent market developments have led to skepticism about the sustainability of SK3's growth, with some analysts questioning its long-term strategy.
- Insider selling activity in the past raised red flags, leading to doubts about the company's immediate prospects and management confidence.
- Overall market volatility has created a cautious environment, with investors wary of potential downturns affecting SK3's performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SKTO Latest News
No recent news available for SKTO.
SKTO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SKTO.
Price Targets
Wall Street price target analysis for SKTO.
SKTO MoonshotScore
What does this score mean?
The MoonshotScore rates SKTO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
SKTO OTC Market Information
SKTO trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
SK3 Group, Inc. Healthcare Stock: Key Questions Answered
What does SK3 Group, Inc. do?
SK3 Group, Inc. operates in the medical marijuana sector, providing management advisory, licensing, and marketing services to medical marijuana collectives in California. The company licenses various products, including edibles, delivery systems, and pre-rolls, and also offers its proprietary Dharmanol technology for cannabinoid extraction and preservation. Its business model focuses on supporting the operations of medical marijuana collectives through licensing agreements and advisory services within the California market.
What are the main risks for SKTO?
The main risks for SK3 Group, Inc. include regulatory changes in California and at the federal level, increased competition from larger cannabis companies, and potential product liability claims. As a small company operating in a highly regulated industry, SK3 Group, Inc. is vulnerable to shifts in the legal landscape. Increased competition could erode its market share and pricing power.
What are the key factors to evaluate for SKTO?
Evaluate SKTO on fundamentals, analyst consensus, and risk factors. P/E: 0.0x vs the S&P 500's ~20-25x. SK3 Group, Inc. Not financial advice.
How frequently does SKTO data refresh on this page?
SKTO's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SKTO's recent stock price performance?
SK3 Group, Inc. (SKTO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Dharmanol technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SKTO overvalued or undervalued right now?
SK3 Group, Inc. (SKTO) trades at 0.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SKTO before investing?
Before investing in SK3 Group, Inc. (SKTO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SKTO to a portfolio?
Key strength of SK3 Group, Inc. (SKTO): Proprietary Dharmanol technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to the company's size and OTC listing.
- AI analysis is pending and may provide further insights.